Valuation: Innoviva, Inc.

Market Cap 1.64B 1.44B 1.33B 1.23B 2.32B 157B 2.36B 15.87B 6.23B 77.05B 6.16B 6.02B 266B P/E 2026 *
6.65x
P/E 2027 * 9.71x
Enterprise Value 1.13B 987M 914M 841M 1.59B 108B 1.62B 10.89B 4.27B 52.89B 4.23B 4.13B 183B EV / Sales 2026 *
2.55x
EV / Sales 2027 * 1.87x
Free-Float
99.01%
Yield 2026 *
-
Yield 2027 * -
1 day-0.13%
1 week+1.79%
Current month-2.20%
1 month-2.33%
3 months-7.34%
6 months+13.84%
Current year+11.11%
1 week 21.95
Extreme 21.95
22.73
1 month 21.7
Extreme 21.7
24.17
Current year 19
Extreme 19
25.14
1 year 16.52
Extreme 16.52
25.14
3 years 12.22
Extreme 12.22
25.14
5 years 10.64
Extreme 10.64
25.14
10 years 7.58
Extreme 7.58
25.14
Manager TitleAgeSince
Chief Executive Officer 42 2020-05-19
Director of Finance/CFO 60 2023-08-20
Investor Relations Contact - 2025-08-31
Director TitleAgeSince
Director/Board Member 75 2018-02-11
Director/Board Member 66 2018-02-11
Director/Board Member 42 2025-05-18
Date Insider Type Main position Quantity % Market Cap.
05-19Tax

Controller/Auditor

-1,127 0.0015%
05-19Tax

Chief Financial Officer

-559 0.0008%
05-19Tax

Chief Executive Officer

-1,130 0.0015%
Change 5-day change 1-year change 3-year change Capi.($)
-0.13%+1.79%+18.33%+78.25% 1.64B
-0.56%-1.52%+49.04%+171.88% 1,060B
+0.31%-0.60%+64.29%+62.31% 619B
-0.03%-2.65%+28.86%+85.64% 438B
-1.75%-0.33%+28.78%+23.58% 333B
+0.24%-0.42%+29.46%+47.26% 282B
-1.75%-10.57%+20.67%+22.07% 267B
+0.67%+1.03%-26.10%-37.96% 218B
-0.81%-1.63%+22.07%+58.33% 196B
+1.21%+1.38%+19.85%+71.29% 161B
Average -0.22%-1.92%+25.52%+58.27% 357.56B
Weighted average by Cap. -0.28%-2.12%+36.26%+83.93%

Financials

2026 *2027 *
Net sales 441M 386M 358M 329M 623M 42.17B 635M 4.27B 1.67B 20.71B 1.65B 1.62B 71.51B 486M 426M 395M 363M 687M 46.52B 701M 4.71B 1.85B 22.85B 1.83B 1.79B 78.9B
Net income 286M 251M 232M 214M 404M 27.37B 412M 2.77B 1.09B 13.44B 1.07B 1.05B 46.41B 185M 162M 150M 138M 262M 17.72B 267M 1.79B 703M 8.7B 695M 680M 30.05B
Net Debt -514M -451M -418M -384M -727M -49.2B -741M -4.98B -1.95B -24.16B -1.93B -1.89B -83.44B -728M -639M -592M -544M -1.03B -69.72B -1.05B -7.05B -2.77B -34.24B -2.74B -2.68B -118B
Logo Innoviva, Inc.
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Employees
159
Date Price Change Volume
26-07-13 US$22.21 -0.13% 592,248
26-07-10 US$22.24 +0.18% 2,676,231
26-07-09 US$22.20 -1.03% 672,068
26-07-08 US$22.43 +0.81% 978,642
26-07-07 US$22.25 +1.97% 513,404
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
22.21USD
Average target price
35.50USD
Spread / Average Target
+59.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INVA Stock